Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection under ordinary light |
| Primary analytical method | Reversed-phase liquid chromatography | Purity estimated from peak area at 214 nm |
| Confirmatory method | Mass spectrometry | Observed mass compared with calculated value |
| Powder storage temperature | Minus 20 degrees Celsius | Minus 80 for extended archival periods |
| Solution stability | Hours to days at 2 to 8 degrees Celsius | Influenced by pH, buffer, and concentration |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
The smallest dinosaur known is the bee hummingbird, with a length of only 5 centimeters (2.0 in) and mass of around 1.8 g (0.063 oz). The smallest known non-avialan dinosaurs were about the size of pigeons and were those theropods most closely related to birds. For example, Anchiornis huxleyi is currently the smallest non-avialan dinosaur described from an adult specimen, with an estimated weight of 110 g (3.9 oz) and a total skeletal length of 34 centimeters (1.12 ft). The smallest herbivorous non-avialan dinosaurs included Microceratus and Wannanosaurus, at about 60 centimeters (2.0 ft) long each.
Single display resolutions One 16K (15360 × 8640) display @ 60 Hz with 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (with DSC) One 10K (10240 × 4320) display @ 60 Hz and 8 bpc (24 bit/px, SDR) RGB/Y′CBCR 4:4:4 color (uncompressed) Dual display resolutions Two 8K (7680 × 4320) displays @ 120 Hz and 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (with DSC) Two 4K (3840 × 2160) displays @ 144 Hz and 8 bpc (24 bit/px, SDR) RGB/Y′CBCR 4:4:4 color (uncompressed) Triple display resolutions Three 10K (10240 × 4320) displays @ 60 Hz and 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (with DSC) Three 4K (3840 × 2160) displays @ 90 Hz and 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (uncompressed) When using only two lanes on the USB-C connector via DP Alt Mode to allow for simultaneous SuperSpeed USB data and video, DP 2.0 can enable such configurations as:
== History == Methenamine was first discovered as a chemical compound in 1859. It was introduced for medical use as a urinary antiseptic under the name Urotropin in 1895. The drug was described as rapidly sterilizing and thereby restoring putrid and pus-filled urine to a normal appearance and constitution. A combination of methenamine with salicylic acid was also developed and introduced the same year. Methenamine was only used as a urinary antiseptic in cases of acidic urine, whereas boric acid was used to treat UTIs with alkaline urine. The drug name methenamine, a contraction of the chemical or scientific name hexamethylenetetramine, was formally introduced and designated by the United States Pharmacopeia (USP) by 1925 and replaced the prior name of the drug that was being used of hexamethylenamine. The alternative drug name hexamine was introduced in the British Pharmacopoeia (BP) by 1914 to be used instead of the commercial name Urotropin. Interest in methenamine declined after the discovery of the antibiotic penicillin in 1928 and it has been described as a "forgotten drug". However, there was a surge of interest in methenamine from the 1950s to the 1980s. The drug was formally approved by the Food and Drug Administration (FDA) for medical use in the United States in 1967. The topical form of methenamine for treatment of hyperhidrosis was introduced around 1965. Subsequently, there was another decline in interest in methenamine from 1980 until 2010.
Re-lactation is the process of restarting breastfeeding. In developing countries, mothers may restart breastfeeding after a weaning as part of an oral rehydration treatment for diarrhea. In developed countries, re-lactation is common after early medical problems are resolved, or because a mother changes her mind about breastfeeding. Re-lactation is most easily accomplished with a newborn or with a baby that was previously breastfeeding; if the baby was initially bottle-fed, the baby may refuse to suckle. If the mother has recently stopped breastfeeding, chances are higher that the milk supply will return and be adequate. Although some mothers successfully re-lactate after months-long interruptions, success is higher for shorter interruptions. Techniques to promote lactation include frequent attempts to breastfeed, extensive skin-to-skin contact with the baby, and frequent, long pumping sessions. Suckling may be encouraged with a tube filled with infant formula, so that the baby associates suckling at the breast with food. A dropper or syringe without the needle may be used to place milk onto the breast while the baby suckles. The mother should allow the infant to suckle at least ten times during 24 hours, and more times if the baby is interested. These times can include every two hours, whenever the baby seems interested, longer at each breast, and when the baby is sleepy, when they might suckle more readily. In keeping with increasing contact between mother and child, including increasing skin-to-skin contact, grandmothers should pull back and help in other ways.
Collectivist and individualistic values also play a role in the manifestation of symptoms. Patients in China are more likely to display denial or minimization of symptoms since they are culturally encouraged to use conceal their symptoms to preserve group harmony. These cultural differences are further empathized in research on the Caribbean island of Curaçao which revealed a substantially lower overall incidence of anorexia nervosa than that observed in the United States and Western Europe. Specifically, no cases were identified among the majority Black population, while the minority mixed and white population showed incidence rates similar to those in Western countries. This disparity highlights potential cultural variations in the development and presentation of anorexia nervosa, particularly when comparing Black women in Curaçao to those exposed to Western cultural influences. Notably, although these cultural distinctions persist, modernization and globalization slowly homogenize these attitudes. Anorexia is increasingly tied to the pressures of a global culture that celebrates Western ideals of thinness. The spread of Western media, fashion, and lifestyle ideals across the globe has begun to shift perceptions and standards of beauty in diverse cultures, contributing to a rise in the incidence of anorexia in places they were once rare. Anorexia, once primarily associated with Western culture, seems more than ever to be linked to the cultures of modernity and globalization.
Sources: en.wikipedia.org
==== Eliminated in primary ==== Daniel Betts, attorney and nominee for Travis County district attorney in 2024 Jason Cahill, businessman Jacques DuBose, former Boerne city councilman Zeke Enriquez, U.S. Marine Corps veteran (previously ran in the 23rd district) Weston Martinez, businessman Paul Rojas, engineer Heather Tessmer, attorney Trey Trainor, former commissioner from the Federal Election Commission (2020–2025) Peggy Wardlaw, engineer and candidate for this district in 2018 Michael Wheeler, senior advisor to the Small Business Administration and former chair of the Kendall County Republican party
Intraoperative stimulation has been employed a prognostic tool in people undergoing neurolysis surgery following nerve injury, where lower stimulation thresholds are associated with better postoperative motor recovery, whereas absent responses are associated with poor motor recovery, potentially warranting additional surgical interventions. Surgery can be done in case a nerve has become cut or otherwise divided, as well as when no recovery is achieved many months after injury. Recovery of a nerve after surgical repair depends mainly on the age of patients. Younger people fare better for prognosis due to the healing capacity of young tissues. Young children can recover almost normal nerve function. In contrast, a person over 60 years old with a cut nerve in the hand would expect to recover only protective sensory function, that is, the ability to distinguish hot/cold or sharp/dull; recovery of motor function would be likely incomplete. Many other factors also affect nerve recovery. An expanding area of nerve regeneration research deals with the development of scaffolding and bio-conduits. Scaffolding developed from bio-compatible material would be useful in nerve regeneration if they successfully exhibit essentially the same role as the endoneurial tubes, Schwann cells and epineurial fibroblasts do in guiding regrowing axons.
Different cecropins act on different types of human cancer cells and show activity at concentrations that are not harmful to normal cells. For example, a recent study of Cecropins A and B demonstrated strongly cytotoxic activity against four bladder cancer cell lines, while benign murine and human fibroblasts were not susceptible to Cecropin A or B. Cecropins from many insect species have been shown to be active against a diverse range of human cancer cell lines. For example, Mdcec, a cecropin originating from the common housefly, has been shown to have an antiproliferative effect on human hepatocellular carcinoma cell line BEL-7402 without affecting normal liver cells. Flow cytometry and RT-PCR experiments revealed that treatment with Mdcec increased expression of pro-apoptotic genes such as caspase-3, leading to cancer cell death. These same genes did not show significant expression changes in healthy cells upon treatment with Mdcec. This suggests a degree of specificity which has promise for development of novel cancer therapies. Further supporting therapeutic efficacy, a study of cecropin A affirmed that cecropin A selectively lyses leukemia cells while exerting little effect on normal lymphocytes. In the same study, chemotherapy drugs cytarabine and 5-fluorouracil synergize with cecropin A in vitro to enhance cytotoxic effects on leukemia cells. This indicates potential for therapeutic application of antimicrobial peptides in cancer, where treatment with cecropins could lower the required dosage of chemotherapy drugs, reducing undesirable side effects.
Romé de l'Isle's Essai de cristallographie published in 1772 and Cristallographie published in 1783 the scientific approach to crystal structure began. Romé de l'Isle described over 500 crystal forms and accurately measured the interfacial angles of a great variety of crystals, using the goniometer designed by his student Arnould Carangeot. Romé de l'Isle noted that the angles are characteristic of a substance, thus generalizing the law of constancy of angles postulated by Steno. Romé de l'Isle considered that the shape of a crystal is a consequence of the packing of elemental particles, and defined six primitive forms. In 1781 René Just Haüy (often termed the "Father of Modern Crystallography") discovered that crystals always cleave along crystallographic planes. Based on this observation, and the fact that the inter-facial angles in each crystal species always have the same value, Haüy concluded that crystals must be periodic and composed of regularly arranged layers of tiny polyhedra (molécules intégrantes). This theory explained why all crystal planes are related by small rational numbers (the law of rational indices). In 1784 René-Just Haüy published Essai d'une théorie sur la structure des cristaux, appliquée à plusieurs genres de substances cristallisées in which he stated his law of decrements: a crystal is composed of molecules arranged periodically in three dimensions without leaving any gaps. Haüy's molecular crystal structure theory assumed that molécules intégrantes were specific in shape and composition for every compound.
Sources: en.wikipedia.org
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.
Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.
Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.